10. November 2009 02:48
Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs. A study in the August issue of Journal of General Internal Medicine found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic equivalents.
[More]
6. November 2009 01:01
NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.
[More]
30. October 2009 08:59
In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.
[More]
abcc0755-d96f-4ed2-bc9b-3df77f99e26c|0|.0
Posted in: Business / Finance
Tags: Ambien, Angioplasty, Antibody, Atrial Fibrillation, Biotechnology, Breast Cancer, Cancer, Cardiology, Cervical Cancer, Chemotherapy, Clopidogrel, Conjunctivitis, Cyclosporine, Dermatology, Diabetes, Diphtheria, Estrogen, Gardasil, H1N1, H5N1, Haemophilus influenzae Type B, Heparin, Hepatitis B, Influenza, Insomnia, Insulin, Lantus, Leukemia, Lymphoma, Meningitis, Monoclonal Antibody, Multaq, Multiple Sclerosis, Oncology, Ophthalmology, Pandemic, Plavix, Pneumonia, Polio, Progesterone, Sleep, Taxotere, Tetanus, Type 2 Diabetes, Vaccine
9. September 2009 01:59
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.
[More]
1. September 2009 04:09
There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.
[More]
d79f42c0-da2f-44a5-8c2c-09a2498e3094|0|.0
Posted in: Medical Research News | Medical Condition News
Tags: Acid Reflux, Ambien, Angina, Anxiety, Barrett's Esophagus, Cancer, Depression, Esophageal Cancer, Gastroenterology, Hepatology, Insomnia, Obesity, Sleep, Smoking, Stroke, Tobacco
31. August 2009 10:47
Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore consciousness for patients in the vegetative state.
[More]
19. January 2009 21:29
Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters.
[More]
10. December 2008 21:18
Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.
[More]
f4f7d136-4b01-4ce0-9154-36bffdc5ec64|0|.0
Posted in: Pharmaceutical News
Tags: Ambien, Angina, Bipolar Disorder, Blood Pressure, Depakote, Divalproex, Fosamax (alendronate sodium), Generic Drug, Glaucoma, Heart Failure, Herpes, Migraine, Osteoporosis, Prescription Drug, Pseudoephedrine, Ramipril, Restless Legs Syndrome, Sleep, Valacyclovir, Zyrtec
1. September 2008 19:56
The Wall Street Journal on Friday examined "unbranded product advertising" for brand-name drugs, which allow drugmakers to drive television viewers to Web sites promoting drugs without the requirement of listing the products' side effects in the TV advertisement.
[More]
27. April 2007 21:59
Ranbaxy Laboratories Limited (RLL), has announced that the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Zolpidem Tartrate Tablets, 5mg and 10mg.
[More]
24. April 2007 07:18
Mylan Laboratories has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Zolpidem Tartrate Tablets, 5 mg and 10 mg.
[More]
24. April 2007 07:06
The U.S. Food and Drug Administration (FDA) today approved the first generic versions of Ambien (zolpidem tartrate) immediate-release tablets.
[More]
14. March 2007 14:29
The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks.
[More]
8. March 2007 04:09
Manufacturers' prices for the 193 prescription drugs most commonly used by U.S. residents ages 50 and older increased at about twice the rate of inflation in 2006, according to an annual report released on Tuesday by AARP, Cox/Atlanta Journal-Constitution reports.
[More]
19. February 2007 06:22
The Food and Drug Administration (FDA) in the United States has again warned consumers about buying medications over the Internet.
[More] 
Subscribe